Background: The use of dopamine agonists (DAs) for the treatment of restless legs
syndrome (RLS) has been assessed in numerous randomized clinical trials (RCTs) …

OBJECTIVE: Restless legs syndrome (RLS) is a common neurological disorder causing
considerable impairment to daily living. This article is an overview of a comprehensive …

PURPOSE We performed a meta-analysis of randomized placebo-controlled trials of
nonergot dopamine agonists (NEDAs) for the treatment of restless legs syndrome …

Background At the time of writing only dopamine agonists are licensed for the treatment of
restless legs syndrome (RLS) in various countries, but randomized controlled trials (RCTs) …

OBJECTIVE: In the absence of comparative trials a meta-analysis was performed to
compare the efficacy and tolerability of the non-ergot derived dopamine agonists …

Dopamine agonists for the treatment of restless legs syndrome - Scholz, H - 2011 | Cochrane
Library Skip to Content Cookies Our site uses cookies to improve your experience. You can …

Objective: A mixed treatment comparison (MTC) was performed to investigate the relative
efficacy and safety of licensed pharmaceuticals for moderate-to-severe restless legs …

Evidence‐based guidelines consider dopaminergic therapy to be the mainstay of treatment
for restless legs syndrome (RLS). l‐dopa has been shown to reduce RLS symptoms, but …

Although various drugs are currently used for restless legs syndrome (RLS) in clinic,
selecting appropriate drugs for patients is difficult. This network meta-analysis (NMA) aimed …

OBJECTIVE: To review the use of newer dopamine agonists, pramipexole and ropinirole, in
the treatment of restless legs syndrome (RLS). DATA SOURCES: Biomedical literature was …